Novartis, Pfizer join forces on potentially lucrative fatty liver disease Business, Diabetes, Epidemics, Liver Disease, Obesity Novartis AG and Pfizer Inc. are teaming up to develop treatments for a liver disease tied to obesity and diabetes epidemics that many drug companies believe will become a hugely lucrative market. Read more October 29, 2018/by Reuters Health https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 Reuters Health https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Reuters Health2018-10-29 02:24:422018-10-29 13:06:21Novartis, Pfizer join forces on potentially lucrative fatty liver disease
